Key Highlights
- Eli Lilly commits $3 billion to Chinese operations throughout the coming decade
- Funding targets manufacturing expansion for orforglipron, the company’s oral GLP-1 obesity treatment
- Marketing authorization request for orforglipron submitted to Chinese regulators in late 2025
- Bernstein maintains Outperform designation with $1,300 price objective; shares currently near $1,008
- LillyConnect employer platform debuts, enabling customized GLP-1 benefits through partnerships with GoodRx and Cost Plus Drugs
Eli Lilly ($LLY) revealed plans Wednesday to deploy $3 billion across China throughout the next ten years. The pharmaceutical giant’s strategy centers on expanding manufacturing infrastructure for orforglipron, its investigational once-daily oral medication designed to treat type-2 diabetes and obesity.
The pharmaceutical company made the disclosure via WeChat, revealing it had already filed a marketing authorization application for orforglipron with Chinese health authorities in December 2025. Regulators are currently evaluating the submission.
Orforglipron represents a non-peptide GLP-1 receptor agonist — distinguishing it mechanistically from Lilly’s currently marketed injectable therapies such as Zepbound. Clinical trial data demonstrated that overweight participants without diabetes achieved average body weight reductions of 12.4% across 72 weeks when administered the highest dosage.
Additional research revealed orforglipron successfully supported weight maintenance in patients transitioning from Zepbound or Novo Nordisk’s Wegovy. This finding holds strategic importance as Lilly pursues expansion within the oral GLP-1 therapeutic category.
Supporting the China initiative, Lilly indicated plans to establish domestic manufacturing infrastructure and supply chain operations for oral solid dosage medications. This approach would minimize import dependencies and optimize regional distribution networks.
The strategic announcement aligns Lilly with other Western pharmaceutical companies strengthening their Chinese presence, including Haleon and AstraZeneca, which disclosed comparable expansion plans during recent months.
The timing carries significance — occurring before an anticipated diplomatic meeting between U.S. President Donald Trump and Chinese President Xi Jinping scheduled for this month.
However, not all pharmaceutical companies share this strategic direction. Bristol-Myers Squibb announced in September its decision to divest its 60% ownership in a Chinese pharmaceutical joint venture, including production facilities in Shanghai.
Bernstein Maintains Bullish $1,300 Price Objective
Bernstein SocGen reaffirmed its Outperform rating alongside a $1,300 price objective for LLY stock this week, following recent developments regarding GLP-1 distribution channels domestically. Shares currently trade around $1,008.
The investment firm emphasized CMS guidance on the BALANCE initiative, which establishes a $245 Medicaid pricing minimum for obesity medications beginning May 2026, with Medicare inclusion starting July 2026. The comprehensive program spans January 2027 through 2031 — extending beyond the current administration’s term.
Bernstein indicated the extended timeframe delivers pricing visibility for Lilly until semaglutide patent protection expires in 2031.
LillyConnect Platform and Prescription Trends
Last week, Lilly introduced LillyConnect, an innovative platform enabling employers to establish dedicated GLP-1 insurance benefits for workforce members. The company has secured partnerships with 15 program administrators, including GoodRx and Mark Cuban’s Cost Plus Drugs, alongside two pharmacy networks: CentreWell and HealthDyne.
The platform provides employers flexibility to tailor coverage parameters and implement cost-sharing arrangements, potentially reducing patient copayments relative to cash-payment alternatives.
Morgan Stanley, maintaining an Overweight rating with a $1,313 objective, characterized the platform introduction as favorable. Deutsche Bank similarly holds a Buy rating with a $1,285 target.
Regarding prescription volume, Mounjaro recorded approximately 724,500 total prescriptions during the week concluding February 27, representing an increase from the previous period. Deutsche Bank identified a 7% week-over-week recovery in overall GLP-1 prescription activity.
Morgan Stanley acknowledged supply limitations had constrained Mounjaro sales in Brazil, though noted a substantial February import rebound suggesting enhanced product availability.
